Please assess the completion status of the following clinical trial:

Trial Title: DFMO in Children With Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and females 12-40 years of age with a clinical diagnosis of T1D within 2 - 8 months after diagnosis at the time of visit 2.~2. Random non-fasting C-peptide level of \>0.2 pmol/mL at visit 1.~3. Positive for any one of the following diabetes-related autoantibodies (mIAA, GADA, IA-2A, or ZnT8A)~4. Treatment naïve of any immunomodulatory agent~5. Normal hearing at screening, defined as acceptable results of pure-tone audiometry (\<20 decibel \[dB\] baseline thresholds for frequencies 250, 500, 1000, and 2000 Hz~Exclusion Criteria:~1. Presence of severe, active disease that interferes with dietary intake or requires the use of chronic medication, with the exception of well-controlled hypothyroidism and mild asthma not requiring oral steroids. Presence of any psychiatric disorder that will affect ability to participate in study.~2. Diabetes other than T1D~3. Chronic illness known to affect glucose metabolism (e.g. Cushing syndrome, polycystic ovarian disorder, cystic fibrosis) or taking medications that affect glucose metabolism (e.g. steroids, metformin)~4. Inability to swallow pills~5. Psychiatric impairment or current use of anti-psychotic medication~6. Any condition that, in the investigator's opinion, may compromise study participation or may confound the interpretation of the study results.~7. Hematologic abnormalities at screening (anemia, leukopenia (particularly neutropenia), or thrombocytopenia)~8. Impaired renal function (assessed by history and BUN/Creatinine, DFMO is renally excreted)~9. Female participants of child-bearing age must not be pregnant and agree to use an effective form of birth control or be abstinent during the study period.~10. BMI \>95% for age and sex

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Difluoromethylornithine (Type: EXPERIMENTAL): Subjects may be given daily dose of DFMO
- Placebo (Type: PLACEBO_COMPARATOR): Subjects may be given daily dose of placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).